home / stock / sngx / sngx news

SNGX News and Press, Soligenix Inc. From 05/28/19

Stock Information
Company Name: Soligenix Inc.
Stock Symbol: SNGX
Market: NASDAQ
Website: soligenix.com
Menu
SNGX SNGX Quote SNGX Short SNGX News SNGX Articles SNGX Message Board
Get SNGX Alerts

News, Short Squeeze, Breakout and More Instantly...
SNGX - Soligenix awarded a subcontract of $600,000 for supporting evaluation of IDR platform technology

Soligenix (NASDAQ: SNGX ) will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of ~$600,000 over 3 years. More news on: Soligenix, Inc., Healthcare stocks news, Read more .....
SNGX - Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents

PRINCETON, N.J. , May 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Solige...

SNGX - Soligenix beats by $0.05, misses on revenue

Soligenix (NASDAQ: SNGX ): Q1 GAAP EPS of -$0.09 beats by $0.05 . More news on: Soligenix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SNGX - Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results

PRINCETON, N.J. , May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its re...
SNGX - Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

PRINCETON, N.J. , April 23, 2019 /PRNewswire/ --   Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an...

SNGX - Soligenix up 16% premarket on advancement of late-stage study of SGX942

Thinly traded nano cap Soligenix (NASDAQ: SNGX ) is up  16%  premarket on light volume in response to its announcement that enrollment in its Phase 3 clinical trial, DOM-INNATE , evaluating SGX942 for the treatment of oral mucositis (OM) in head and neck cancer patients has reac...

SNGX - Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

PRINCETON, N.J. , April 18, 2019 /PRNewswire/ --   Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today th...
SNGX - Soligenix receives $611,000 through tax certificate transfer program

Soligenix (NASDAQ: SNGX ) has received approx. $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program. More news on: Soligenix, Inc., Healthcare stocks news, Read more ...

SNGX - Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

PRINCETON, N.J. , April 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it h...

SNGX - EMA reaches agreement with Soligenix for SGX942 PIP; shares up 10% premarket

The Pediatric Committee (PDCO) of the EMA has agreed to Soligenix's (NASDAQ: SNGX ) Pediatric Investigation Plan (PIP) for SGX942 (dusquetide). The Company may defer conducting the PIP until successful completion of Phase 3 clinical study evaluating SGX942 as a treatment for oral mucositis...
Previous 10 Next 10